ストックスクリーナーアプリを入手
28.97
1.09%
0.46
前日終値:
$28.51
開ける：
$28.96
24時間の取引高:
170.68K
Relative Volume:
0.10
時価総額：
$4.56B
収益：
$705.14M
当期純損益:
$-453.90M
株価収益率:
-9.5296
EPS:
-3.04
ネットキャッシュフロー:
$-551.29M
1週間 パフォーマンス:
+1.55%
1か月 パフォーマンス:
-12.43%
6か月 パフォーマンス:
-25.49%
1年 パフォーマンス:
-29.83%
1日の値動き範囲:
$28.46
$29.31
1週間の範囲:
$27.57
$29.31
52週間の値動き範囲:
$23.95
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
名前
Ionis Pharmaceuticals Inc
セクター
電話
(760) 931-9200
住所
2855 GAZELLE COURT, CARLSBAD, CA
IONS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
29.00 | 4.56B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.39 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.91 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.29 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.39 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
247.85 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-07 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Neutral |
| 2024-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 再開されました | Jefferies | Buy |
| 2024-06-14 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-10-23 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 開始されました | Raymond James | Strong Buy |
| 2023-07-31 | アップグレード | Citigroup | Neutral → Buy |
| 2023-06-07 | 再開されました | Piper Sandler | Overweight |
| 2023-05-04 | アップグレード | Citigroup | Sell → Neutral |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2022-12-21 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 再開されました | Morgan Stanley | Overweight |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-31 | 再開されました | Piper Sandler | Overweight |
| 2022-03-01 | 開始されました | Citigroup | Sell |
| 2022-03-01 | 開始されました | Guggenheim | Buy |
| 2022-02-01 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-14 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | アップグレード | UBS | Sell → Neutral |
| 2021-03-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 開始されました | UBS | Sell |
| 2020-12-15 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-09-14 | 再開されました | JP Morgan | Neutral |
| 2020-09-02 | 開始されました | The Benchmark Company | Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-13 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-11-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 繰り返されました | Stifel | Hold |
| 2018-08-07 | 繰り返されました | Stifel | Hold |
| 2018-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 再開されました | Goldman | Sell |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-08-09 | 繰り返されました | Stifel | Hold |
| 2017-03-10 | ダウングレード | Goldman | Neutral → Sell |
| 2016-12-28 | 繰り返されました | BMO Capital Markets | Outperform |
| 2016-12-27 | 繰り返されました | Leerink Partners | Mkt Perform |
すべてを表示
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt In A Risky Way? - simplywall.st
Ionis Pharmaceuticals EVP Jenne Kyle sells $85,533 in stock - Investing.com Australia
Ionis Pharmaceuticals EVP Jenne Kyle sells $85,533 in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals EVP Brian Birchler sells $19,291 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP Joseph Baroldi sells $111,555 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP Joseph Baroldi sells $111,555 in stock - Investing.com
Lobbying Update: $90,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
Ionis to hold first quarter 2025 financial results webcast - BioSpace
Ionis Q1 2025 Earnings Call: Key Date and Details for Investors Revealed - Stock Titan
Ionis Pharmaceuticals (IONS) Sees Price Target Cut by Morgan Sta - GuruFocus
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains? - MSN
Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com
Global Antisense & RNAi Therapeutics Market to Witness Massive - openPR.com
Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com
Transthyretin Amyloid Cardiomyopathy Treatment Market Set - openPR.com
Ionis at Needham Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com UK
Ionis Pharmaceuticals initiated with a Buy at H.C. Wainwright - MSN
HC Wainwright & Co. Initiates Coverage of Ionis Pharmaceuticals (IONS) with Buy Recommendation - MSN
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth' - Benzinga
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Ionis Pharma stock hits 52-week low at $26.65 amid market challenges - Investing.com
H.C. Wainwright initiates coverage for Ionis Pharma with 'buy' rating citing pending drug launches - TradingView
H.C. Wainwright initiated coverage on Ionis Pharma with a new price target - Quantisnow
HC Wainwright Initiates Ionis Pharmaceuticals With Buy Rating, $45 Price Target - MarketScreener
H.C. Wainwright sets Ionis stock Buy rating, $45 target By Investing.com - Investing.com UK
Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com
Ionis to host expert panel discussion on sHTG - The Joplin Globe
Leading Medical Experts Reveal Latest Insights on Severe HTG Treatment Landscape - Stock Titan
Treatment-resistant Hypertension Market Growth Projections 2024-2034: DelveInsight Analysis | Idorsia Pharma, Ionis Pharma, KBP Biosciences, KBP Biosciences, Quantum Genomics - Barchart.com
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease - Biogen
10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io
Redburn Atlantic Initiates Coverage of Ionis Pharmaceuticals (IONS) with Neutral Recommendation - MSN
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts - Benzinga
Redburn Atlantic initiated coverage on Ionis Pharma with a new price target - Quantisnow
Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target - MarketScreener
Ionis to present at upcoming investor conferences - The Joplin Globe
Redburn initiates Ionis stock with Neutral, sets $39 target - Investing.com India
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi - MSN
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. - MSN
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
RNA Biotechs: Current State And Outlook - Seeking Alpha
Ionis and Sobi agree on olezarsen commercialisation - Yahoo
Ionis licenses olezarsen to Sobi for global reach By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals Inc (IONS) 財務データ
収益
当期純利益
現金流量
EPS
Ionis Pharmaceuticals Inc (IONS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Birchler Brian | EVP, Corp and Development Ops |
Apr 16 '25 |
Sale |
28.37 |
680 |
19,292 |
56,660 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr |
Apr 15 '25 |
Option Exercise |
0.00 |
12,226 |
0 |
14,215 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr |
Apr 16 '25 |
Sale |
28.36 |
3,016 |
85,534 |
11,199 |
| Baroldi Joseph | EVP, Chief Business Officer |
Apr 15 '25 |
Option Exercise |
0.00 |
10,837 |
0 |
35,854 |
| Baroldi Joseph | EVP, Chief Business Officer |
Apr 16 '25 |
Sale |
28.40 |
3,928 |
111,555 |
31,926 |
1.75%
2.22%
大文字化:
|
ボリューム (24 時間):